FDA Oncology Announcements

Announcements Trials

CXCR4 inhibitor × Other × Clear all

Conditions

Drug Classes

Anti-PD-1 16 Anti-CD20 10 Anti-VEGFR 10 Bcr-Abl inhibitor 10 MTOR inhibitor 10 Taxane 9 VEGFR inhibitor 9 Anti-HER2 7 Megakaryocyte growth factor 7 Anti-EGFR 6 EGFR inhibitor 6 Immunomodulatory drugs (IMiDs) 6 MEK inhibitor 6 ALK inhibitor 5 Antifolate 5 BTK inhibitor 5 Multikinase inhibitor 5 Nitrogen mustard 5 Anti-PD-L1 4 JAK inhibitor 4 Platinum agent 4 Proteasome inhibitor 4 Anti-RANKL 3 Asparagine-specific enzyme 3 BRAF inhibitor 3 HDAC inhibitor 3 Non-taxane microtubule dynamics inhibitor 3 Anthracycline 2 Anti-CD19-CD3 bispecific 2 Anti-CD30 ADC 2 Anti-CD38 2 Anti-CTLA-4 2 Aromatase inhibitor third generation 2 CDK inhibitor 2 CYP17 inhibitor 2 Erythrocyte growth factor 2 Factor IXa/Xa bridging 2 Fluoropyrimidine 2 Granulocyte colony-stimulating factor 2 Low molecular weight heparin 2 PARP inhibitor 2 Pyrimidine analog 2 SMO inhibitor 2 Alkylating agent 1 Anti-C5 1 Anti-CSF1R 1 Anti-EGFR-HGFR bispecific 1 Anti-GD2 1 Anti-HER2 ADC 1 Anti-IL-2R immunotoxin 1 Anti-IL-6 1 Anti-P-selectin 1 Anti-PDGFR 1 Anti-SLAMF7 1 Anti-dabigatran antibody fragment 1 Anti-vWF 1 Antimetabolite 1 Bcl-2 inhibitor 1 CXCR4 inhibitor 1 Cellular therapy 1 Chemotherapy protective agent 1 EDTA derivative 1 ERBB2 inhibitor 1 Estrogen receptor inhibitor 1 Factor Xa inhibitor 1 GnRH antagonist 1 HIF-2a inhibitor 1 Hemoglobin S polymerization inhibitor 1 Interferon 1 Iron chelating agent 1 Oncolytic viral therapy 1 PI3K alpha inhibitor 1 PI3K delta inhibitor 1 Profibrinolytic 1 Purine analog 1 ROCK2 inhibitor 1 Replacement therapy 1 SYK inhibitor 1 Second-generation nonsteroidal antiandrogen 1 Selective estrogen receptor modulator 1 Somatostatin analog 1 TGF-beta inhibitor 1 TRK inhibitor 1 Topoisomerase I inhibitor 1 Triazene 1 Vinca alkaloid 1

1 Announcement

Plerixafor

Drug: Mozobil (plerixafor) · CXCR4 inhibitor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡